5
Participants
Start Date
April 27, 2017
Primary Completion Date
April 25, 2018
Study Completion Date
April 25, 2018
MOXR0916
MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
Atezolizumab
Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
GasthuisZusters Antwerpen, Wilrijk
Columbia University Medical Center; Clinical Research Management Office, New York
New York Oncology Hematology, P.C., Albany
Maryland Oncology Hematology, P.A., Columbia
Virginia Oncology Associates - Lake Wright Cancer Center, Norfolk
Miami Cancer Institute of Baptist Health, Inc., Miami
Sarah Cannon Research Inst., Nashville
SCRI Tennessee Oncology Chattanooga, Chattanooga
Onc/Hem Care Clin Trials LLC, Cincinnati
University of Chicago; Hematology/Oncology, Chicago
Kansas City - Menorah Medical Center, Kansas City
Nebraska Methodist Hospital; Cancer Center, Omaha
Texas Oncology-Baylor Sammons Cancer Center, Dallas
University of Colorado, Denver
Arizona Oncology - HOPE Wilmot, Tucson
Yale University, New Haven
Princess Margaret Cancer Center, Toronto
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center - Oncology, Seoul
Leicester Royal Infirmary NHS Trust, Leicester
Barts and the London NHS Trust., London
Lead Sponsor
Genentech, Inc.
INDUSTRY